Document Type : Original Article


1 Department of Biotechnology and Microbiology, Karnatak University Dharwad, Karnataka, India

2 Department of Zoology, KLES B. K. Arts, Science and Commerce College, Chikodi, Karnataka, India

3 Urinary Biomarkers Research Centre, Department of Urology, KLES Dr. Prabhakar Kore Hospital and Medical Research Centre, Belagavi-590010, Karnataka, India

4 Department of Biotechnology, KAHER’s Dr. Prabhakar Kore Basic and Applied Science Research Center, V. K. Institute of Dental Sciences Campus, Karnataka, India


Background: Understanding the prevalence, clinical characteristics, and changing demographics of Indian bladder cancer (BC) has emerged as an important field of study. Herein, we aimed to present the case series of BC patients of a single tertiary care centre in North Karnataka.
Method: This retrospective study was designed for 14 years from 2004 to 2017, conducted in the urology clinic. A total of 468 newly diagnosed BC patients (male = 415; female = 53) were included in the study. Sociodemographic, clinical characteristics, cystoscopic, and pathological findings were recorded and analyzed via IBM SPSS statistics software Inc. version 20.0.
Results: The mean age of the patients was male = 62.27 years and female = 54.22 years. Hematuria was a common clinical symptom in both genders accounting for 42.02 versus 45.28% of the male and female subjects, respectively. Transition cell carcinoma (TCC) was the common variant seen in the male and female participants (92.99 versus 94.88%, respectively). Low-grade cancer was found in patients with >60 years of age in 39.7% versus 42.1% of respectively the males and females (P = 0.002) as compared to the patients <60 years. Non-muscle invasive BC in the males and females was respectively 55.42% versus 52.83%, whereas muscle-invasive cancer was 44.57% versus 47.16% respectively in the two groups (P = 0.008). 53 patients (29.22%) in the both genders received transurethral resection/intravesical Bacilli Calmette-Guerin therapy, which showed a significant improvement (P = 0.019).
Conclusion: Transition cell carcinoma was found to remain the predominant type of BC with painless hematuria in North Karnataka population. This has seriously affected the public health; this trend is expected to be continued due to the high prevalence of smoking. There should be further emphasis on primary prevention of BC by conducting smoking cessation awareness programs.


How to cite this article:

Puranik SI, Ghagane SC, Nerli RB, Hiremath MB. Incidence of bladder cancer at a tertiary care centre in north Karnataka. Middle East J Cancer. 2022;13(2):363-71. doi: 10. 30476/mejc.2021.86866.1374.

1. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr
H, Karakiewicz P, et al. Epidemiology and risk factors
of urothelial bladder cancer. Eur Urol. 2013;63(2):234-
41. doi: 10.1016/j.eururo.2012.07.033.
2. Singh JP, Priyadarshi V, Pal DK. A clinicoepidemiological
study of young age bladder tumors: An eastern
Indian scenario. J Cancer Res Ther. 2016;12(2):751-
4. doi: 10.4103/0973-1482.154028.
3. van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief
CG, Sylvester RJ, et al. Recurrence and progression
of disease in non-muscle-invasive bladder cancer:
from epidemiology to treatment strategy. Eur Urol.
2009;56(3):430-42. doi: 10.1016/j.eururo.2009.06.028.
4. Gupta P, Jain M, Kapoor R, Muruganandham K,
Srivastava A, Mandhani A. Impact of age and gender
on the clinicopathological characteristics of bladder
cancer. Indian J Urol. 2009;25(2):207-10. doi:
5. Balaji V, Seshiah V, Ashtalakshmi G, Ramanan SG,
Janarthinakani M. A retrospective study on finding correlation of pioglitazone and incidences of bladder
cancer in the Indian population. Indian J Endocrinol
Metab. 2014;18(3):425-7. doi:10.4103/2230-8210.
6. Ghagane S, Nerli R, Hiremath M, Wagh A, Magdum
P. Incidence of prostate cancer at a single tertiary care
center in North Karnataka. Indian J Cancer. 2016;
53:429-31. doi: 10.4103/0019-509X.200671.
7. Yuvaraja TB, Waigankar S, Bakshi G, Prakash G.
Genitourinary cancers: Summary of Indian data. South
Asian J Cancer. 2016;5(3):122-4. doi:10.4103/2278-
8. Freedman ND, Silverman DT, Hollenbeck AR,
Schatzkin A, Abnet CC. Association between smoking
and risk of bladder cancer among men and women.
JAMA. 2011;306(7):737-45. doi:10.1001/jama.
9. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr
H, Karakiewicz P, et al. Epidemiology and risk factors
of urothelial bladder cancer. Eur Urol. 2013;63(2):234-
41. doi: 10.1016/j.eururo.2012.07.033.
10. Witjes JA, Compérat E, Cowan NC, De Santis M,
Gakis G, Lebret T, et al. EAU guidelines on muscleinvasive
and metastatic bladder cancer: summary of
the 2013 guidelines. Eur Urol. 2014;65(4):778-92.
doi: 10.1016/j.eururo.2013.11.046.
11. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal
A, Bray F. Bladder cancer incidence and mortality: a
global overview and recent trends. Eur Urol. 2017;
71(1):96-108. doi: 10.1016/j.eururo.2016.06.010.
12. Srivastava P, Kapoor R, Mittal RD. Association of
single nucleotide polymorphisms in promoter of matrix
metalloproteinase-2, 8 genes with bladder cancer risk
in Northern India. Urol Oncol. 2013;31(2):247-54.
doi: 10.1016/j.urolonc.2011.01.001.
13. Brausi M, Witjes JA, Lamm D, Persad R, Palou J,
Colombel M, et al. A review of current guidelines and
best practice recommendations for the management
of nonmuscle invasive bladder cancer by the
International Bladder Cancer Group. J Urol.
2011;186(6):2158-67. doi: 10.1016/j.juro.2011.07.076.
14. Alfred Witjes J, Lebret T, Compérat EM, Cowan NC,
De Santis M, Bruins HM, et al. Updated 2016 EAU
guidelines on muscle-invasive and metastatic bladder
cancer. Eur Urol. 2017;71(3):462-75. doi: 10.1016/j.
15. Choi W, Porten S, Kim S, Willis D, Plimack ER,
Hoffman-Censits J, et al. Identification of distinct
basal and luminal subtypes of muscle-invasive bladder
cancer with different sensitivities to frontline
chemotherapy. Cancer Cell. 2014;25(2):152-65. doi:
16. Royce TJ, Feldman AS, Mossanen M, Yang JC, Shipley
WU, Pandharipande PV, et al. Comparative
effectiveness of bladder-preserving tri-modality therapy
versus radical cystectomy for muscle-invasive bladder
cancer. Clin Genitourin Cancer. 2019;17(1):23-31.
e3. doi: 10.1016/j.clgc.2018.09.023.
17. Babjuk M. Trends in bladder cancer incidence and
mortality: Success or disappointment? Eur Urol.
2017;71(1):109-10. doi: 10.1016/j.eururo.2016.06.
18. Lerner SP, Dinney C, Kamat A, Bivalacqua TJ, Nielsen
M, O'Donnell M, et al. Clarification of bladder cancer
disease states following treatment of patients with
intravesical BCG. Bladder Cancer. 2015;1(1):29-30.
doi: 10.3233/BLC-159002.
19. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers
C, Rebelo M, et al. Cancer incidence and mortality
worldwide: sources, methods and major patterns in
GLOBOCAN 2012. Int J Cancer. 2015;136(5): E359-
86. doi: 10.1002/ijc.29210.
20. Knowles MA, Hurst CD. Molecular biology of bladder
cancer: new insights into pathogenesis and clinical
diversity. Nat Rev Cancer. 2015;15(1):25-41. doi:
21. Sanli O, Dobruch J, Knowles MA, Burger M,
Alemozaffar M, Nielsen ME, et al. Bladder cancer.
Nat Rev Dis Primers. 2017; 3:17022. doi: 10.
22. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J,
Guo G, Cherniack AD, et al. Comprehensive molecular
characterization of muscle-invasive bladder cancer.
Cell. 2017; 171(3):540-56. doi: 10.1016/j.cell.2017.
23. Seiler R, Ashab HAD, Erho N, van Rhijn BWG,
Winters B, Douglas J, et al. Impact of molecular
subtypes in muscle-invasive bladder cancer on
predicting response and survival after neoadjuvant
chemotherapy. Eur Urol. 2017;72(4):544-54. doi:
24. Silverman DT, Hartge P, Morrison AS, Devesa SS.
Epidemiology of bladder cancer. Hematology/
Oncology Clinics of North America. 1992;6(1):1-30.
25. Nerli RB, Reddy M, Koura AC, Prabha V, Ravish IR,
Amarkhed S. Cystoscopy-assisted laparoscopic partial
cystectomy. J Endourol. 2008;22(1):83-6. doi:
26. Colmers IN, Majumdar SR, Yasui Y, Bowker SL,
Marra CA, Johnson JA. Detection bias and
overestimation of bladder cancer risk in type 2 diabetes:
a matched cohort study. Diabetes Care. 2013;36(10):